Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
According to Regentis, GelrinC addresses a significant unmet medical need. The company estimates that approximately 470,000 cases of cartilage knee repair occur annually in the United States alone, where no off-the-shelf treatment is currently available. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The training program is designed to ensure that surgeons are proficient in the GelrinC implantation technique before the product is widely marketed. By establishing Centers of Excellence, Regentis aims to create a network of experienced clinicians who can serve as mentors and resources for other surgeons adopting the technology. This approach is common in the medical device industry, where hands-on training and peer-to-peer learning are critical for successful product adoption.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company’s lead product, GelrinC, has received CE Mark approval, allowing it to be marketed in the European Union.
For more information about Regentis Biomaterials and its latest news, visit the company’s newsroom at https://ibn.fm/RGNT. The full press release is available at https://ibn.fm/QOWWK.
